PT - JOURNAL ARTICLE AU - Shira Ben Porat AU - Daniel Gelman AU - Ortal Yerushalmy AU - Sivan Alkalay-Oren AU - Shunit Coppenhagen-Glazer AU - Malena Cohen-Cymberknoh AU - Eitan Kerem AU - Israel Amirav AU - Ran Nir-Paz AU - Ronen Hazan TI - Expanding Clinical Phage Microbiology: Simulating Phage Inhalation for Respiratory Tract Infections AID - 10.1101/2021.06.14.448272 DP - 2021 Jan 01 TA - bioRxiv PG - 2021.06.14.448272 4099 - http://biorxiv.org/content/early/2021/06/14/2021.06.14.448272.short 4100 - http://biorxiv.org/content/early/2021/06/14/2021.06.14.448272.full AB - Phage therapy is a promising antibacterial strategy for resistant respiratory tract infections. Phage inhalation may serve this goal; however, it requires a careful assessment of their delivery by this approach. Here we present an in-vitro model to evaluate phage inhalation.Eight phages, most of which target CF-common pathogens, were aerosolized and administered to a real-scale CTâ–¡derived 3D airways model with a breathing simulator. Viable phage loads reaching the output of the nebulizer and the tracheal level of the model were determined and compared to the loaded amount.Phage inhalation resulted in a diverse range of titer reduction, primarily associated with the nebulization process. No correlation was found between phage delivery to the phage physical or genomic dimensions. These findings highlight the need for tailored simulations of phage delivery, ideally by a patient-specific model in addition to proper phage matching, to increase the potential of phage therapy success.Take-Home Message Phage therapy can be used against infectious diseases if personally tailored. Using a 3D airways model, we show that phage delivery by inhalation to the respiratory tract is unpredictable and also requires a precise evaluation.Competing Interest StatementThe authors have declared no competing interest.